TAA Concealment Strategy to Minimize On-target, Off-tumor Toxicity

Key challenges include on-target, off-tumor toxicity due to TAA expression in healthy tissues and cytokine release syndrome (CRS) from broad systemic T-cell activation.

In contrast to traditional antibodies or current conditionally activated antibodies (such as masking or pH-dependency), which modulate T-cell or TAA binding through stimulus-driven activation to overcome these challenges, our innovative CrossBody TCEs demonstrate exceptionally enhanced therapeutic index without requiring antibody modification or external stimuli. This is purely attributed to the unique mechanism of action (MOA) of our proprietary CrossBody technology, which allows for flexible modulation of T-cell and tumor cell binding through featuring a novel CrossBody fragment or via concealment strategy (not masking or caged). This innovative technology enables the targeting of previously undruggable targets, such as low-expressed tumor-specific antigens (TSAs) and TAAs that are highly expressed in both tumors and normal cells.